← SynDRA
MARDEPODECT
SynDRA canonical compound SYN0019393 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | PDE10A |
|---|
| Mechanism of action | Phosphodiesterase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- Phosphodiesterase inhibitor
- PDE10A INHIBITOR
- Phosphodiesterase 10A inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- LGALS3
- PDE1C
- PDE4D
- PDE9A
- ABL1
- AURKA
- BRD4
- BRPF1
- CDK2
- CSNK1D
- FGFR2
- GSK3B
- HDAC6
- MAPK1
- TRIM24
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- CP2C9
- CP2D6
- CP3A7
- IFNG
- KSYK
- NSD2
- SYK
Cross-references
Synonyms
- MP-10
- PF-02545920
- PF-2545920
- 2-((4-(1-Methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinoline succinate
- UNII-TJ5KAZ8T5G
- TJ5KAZ8T5G
- PF-2545920 succinate
- SCHEMBL439127
- CTK8C0559
- DTXSID90647726
- ANW-64894
- AKOS016005150
- KB-80291
- Quinoline, 2-((4-(1-methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl)phenoxy)methyl)-, butanedioate (1:1)
- AX8234870
- TC-153639
- Quinoline,2-[[4-[1-methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenoxy]methyl]-,succinate salt
- 2-[[4-[1-Methyl-4-(4-pyridyl)pyrazol-3-yl]phenoxy]methyl]quinoline
- ((11)C)MP-10
- RefChem:810610
- PF 2545920
- Mardepodect [USAN]
- Mardepodect free base
- R9Y8EY0G42
- [11C]MP 10
- PF2545920
- UNII-R9Y8EY0G42
- PF9
- MFCD09743765
- MFCD28144518
- 3hr1
- substituted pyrazole, 9
- MARDEPODECT [INN]
- Mardepodect (USAN/INN)
- PF-0254920
- MARDEPODECT [WHO-DD]
- MLS006011117
- PDE10A-IN-4
- GTPL9617
Look up MARDEPODECT in the interactive SynDRA portal →